-
Single drug retail enterprises are accelerating their exit!
Time of Update: 2022-04-24
Recently, the Bengbu Market Supervision and Administration Bureau issued a notice on the cancellation of the "Drug Business License".
Among them, 125 single drugstores and chain stores were inspected, 3 unqualified enterprises, 14 rectification enterprises within a time limit, and 108 qualified enterprises .
-
Blockbuster ovarian cancer ADC drug under development is expected to submit BLA in the United States this month!
Time of Update: 2022-04-24
In addition, in the Chinese market, the first clinical trial application of Mirvetuximab in China was approved by the National Medical Products Administration (NMPA) in March 2021, including the above-mentioned international multi-center Phase III study and a safety evaluation in Chinese adult patients.
-
The performance of pharmaceutical companies is outstanding. Which sectors are expected to grow rapidly in the first quarter of 2022?
Time of Update: 2022-04-23
In addition, the net profit of Orient Bio, Wantai Bio, and Zuoli Pharmaceutical in 2021 will all increase by more than 100% year-on-year .
For the growth of performance, increasing investment in research and development is an important driving force for many companies .
-
The acceleration of the modernization of traditional Chinese medicine may benefit the leading pharmaceutical equipment companies
Time of Update: 2022-04-23
With the support of favorable policies, the modernization of traditional Chinese medicine has accelerated, and the industry will also speed up in the direction of intelligent manufacturing.
-
A large number of pharmaceutical companies continue to increase their R&D investment, injecting new momentum into development
Time of Update: 2022-04-23
Dizhe Pharmaceutical's financial report shows that during the reporting period, the company invested 588 million yuan in research and development, a year-on-year increase of 33.
In 2021, the company's research and development investment will account for nearly 10% of sales revenue, reaching more than 3 billion yuan .
-
With the help of policies, the standardization development of Chinese herbal medicines is on the fast track
Time of Update: 2022-04-23
Recently, in addition to the new version of the "Quality Management Standards for the Production of Chinese Medicinal Materials" jointly issued by the four departments, many regions have also made it clear that they will promote the standardization and modernization of Chinese medicinal materials industry.
-
"Quality Management Practices for Drug Distribution - Appendix for Quality Management of Drug Retail Distribution (Draft for Comment)" released
Time of Update: 2022-04-23
Article 6 Drug retail enterprises shall, in accordance with the relevant provisions of the "Specifications", formulate a quality management system for drug distribution, including personnel management, job responsibilities, facilities and equipment, operating procedures, records and vouchers, emergency management, etc.
-
The profits of multiple pharmaceutical companies have risen 10 times, and a pharmaceutical company has gained 11 daily limits. In the industry: investment opportunities outweigh risks
Time of Update: 2022-04-23
However, on the evening of March 21, China Pharmaceutical issued a risk warning announcement saying, "Since March 2, 2022, the company's stock price has increased by nearly 230%, and it has encountered abnormal fluctuations in stock trading five times .
-
Innovent's small-molecule antitumor drug pemigatinib for cholangiocarcinoma is expected to be approved in the near future
Time of Update: 2022-04-23
cn/v5/home/)The marketing application of pimetinib in China is based on a trial in subjects with FGFR2 fusion or rearrangement, unresectable locally advanced, recurrent or metastatic cholangiocarcinoma who have failed at least one line of systemic therapy Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib .
-
This pharmaceutical company has 3 new Class 1 drugs that are about to be launched, and the Nuggets ADC track
Time of Update: 2022-04-23
In addition, Rongchang Bio has 4 new class 1 drugs that have entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications), namely RC88, RC98, RC108 and RC118, all of which are in the clinical phase I stage .
-
The State Food and Drug Administration revises the drug insert of the children's phlegm-relieving and cough-relieving preparations
Time of Update: 2022-04-23
The item [adverse reactions] should include: Monitoring data show that children's anti-phlegm and anti-cough preparations have vomiting, nausea, diarrhea, abdominal pain, rash, itching, sweating, dizziness, Headache, allergic reaction and other adverse reaction reports .
-
The introduction of new regulations on medical device production and operation strengthens the supervision and management of medical device registrants
Time of Update: 2022-04-23
Recently, the State Administration for Market Regulation issued the revised "Measures for the Supervision and Administration of Medical Device Production" and "Measures for the Supervision and Admini
-
The gene therapy industry is developing rapidly, and the market size may exceed US$30 billion in 2025
Time of Update: 2022-04-23
The industry believes that with the support of favorable policies, coupled with technological upgrading and capital increase, the cell gene therapy industry will become an emerging development direction in the medical field.
-
In 2021, the investigation and handling of drug cases in my country will continue to increase
Time of Update: 2022-04-23
The effect of quality supervision in the whole life cycle continues to improve In 2021, drug regulatory authorities at all levels will coordinate the use of unannounced inspections, supervision and random inspections, and handling of complaints and reports to timely study and judge new situations and problems, and take effective measures to investigate and resolve the hidden dangers of "two products and one machine", so that supervision runs on risks.
-
Pfizer's ulcerative colitis drug etrasimod successful in phase 3 trial
Time of Update: 2022-04-23
Pfizer said results from another longer-term pivotal study, Elevate 52, will be available at the end of this month, and positive data from both trials will be used in the future to seek FDA approval for etrasimod for ulcerative colitis.
-
150 million yuan cooperation!
Time of Update: 2022-04-23
According to the enterprise analysis module of the Insight database, Junshi Bio has already had 6 new chemical drugs in clinical development in China .
-
Another ophthalmology company landed on the Growth Enterprise Market and rose sharply at the opening
Time of Update: 2022-04-23
It is worth mentioning that after years of practice and in-depth cultivation of ophthalmology specialist diagnosis and treatment services and optometry services, while Ho's Ophthalmology has rich clinical diagnosis and treatment experience and professional technical advantages, its market has begun to expand and its income has also increased.
-
Kelun Pharmaceutical's JAK inhibitor for alopecia areata approved for clinical use
Time of Update: 2022-04-23
According to the Insight database, KL130008 was first approved for clinical use in June 2018 for the treatment of rheumatoid arthritis, and phase II clinical trials have been started .
-
A number of longevity drug concept stocks are booming. Does mastering NMN mean having a wealth code?
Time of Update: 2022-04-22
Recently, NMPA of the State Food and Drug Administration announced the information that NMN (β-nicotinamide mononucleotide) substances can be registered as new raw materials for "cosmetics", which is considered to be a positive signal for the industry .
-
The turnover of personnel in the pharmaceutical industry is frequent, and many executives of pharmaceutical companies have recently resigned
Time of Update: 2022-04-22
Doray Medicine: Several senior executives resigned On March 7, Doray Medicine announced that the company's board of directors recently received a written resignation report submitted by the company's deputy general manager, Mr.
